top of page
CARDIAC MARKERS
Cardiac biomarkers have evolved as essential tools in cardiology over the last 50 years, that is, for primary and secondary prevention, the diagnosis and management of acute myocardial infarction (AMI), and the diagnosis and risk stratification of heart failure (HF).
​
We are beginning an era when it may be possible for biomarkers to direct treatment to optimize patient management. This is already the case with cardiac troponin (cTn) but should be the goal with all biomarkers. This special issue is a compilation of timely reviews and original articles on this topic.
bottom of page